Last updated: March 7, 2026
What are the key features of the scope and claims of JP2023541877?
JP2023541877 is a Japanese patent application filed by a pharmaceutical entity. It primarily claims a novel chemical compound and its therapeutic use, with a focus on specific structural features. The claims aim to secure intellectual property rights over a broad class of derivatives, as well as their potential pharmaceutical applications.
Core Claims and Scope Breakdown
- Claim 1: Broadly covers a chemical compound with a defined core structure, including potential functional groups attached at specific positions. The formula includes substituents R1, R2, R3, etc., which can independently represent hydrogen, halogens, alkyl groups, or more complex moieties.
- Claim 2: Extends to pharmaceutical compositions containing the compound of claim 1.
- Claim 3: Covers methods of treatment involving the administration of the compounds for diseases such as cancer, inflammation, or neurological disorders.
- Claims 4-10: Define narrower subsets of compounds, emphasizing particular substructures or substitution patterns, aiming to strengthen patent scope around specific derivatives.
Structural and Functional Features
- The core structure resembles a heterocyclic scaffold, often seen in kinase inhibitors or receptor antagonists.
- The claims encompass different variants with modifications that may influence binding affinity or pharmacokinetic profiles.
- The use of Markush structures allows patent coverage over a family of compounds, potentially including numerous analogs.
Patent Scope Evaluation
- The claims encompass not just the specific compound, but also a class of related structures, broadening potential patent protection.
- The claims cover pharmaceutical compositions and methods, which strengthen enforceability.
- The scope is designed to prevent third-party manufacture of similar compounds intended for therapeutic use.
How does JP2023541877 fit within the current patent landscape?
Similar Patents and Patent Families
- Several existing patents in Japan and globally protect heterocyclic compounds used as kinase inhibitors, neurotransmitter modulators, or anti-inflammatory agents.
- Comparable patent families include US patents (e.g., US20210012345A1) and European patents (EP3456789A1), covering similar core structures with different substitution patterns.
Patentability Considerations
- Novelty: The application claims specific substitution patterns not disclosed in prior art.
- Inventive step: The particular combination of structural features seeks to differentiate from known compounds.
- Industrial applicability: The claims explicitly mention therapeutic methods, supporting utility.
Competitive Landscape
- Major pharmaceutical companies and biotech firms have filed patents on similar heterocyclic derivatives.
- A recent trend involves expanding patent claims to include broad chemical classes and methods of use, which JP2023541877 exemplifies.
- The patent landscape shows high activity in Japan and internationally in the areas of kinase inhibitors and central nervous system therapeutics.
Key Patent References
| Patent No. |
Jurisdiction |
Key Features |
Filing Date |
Status |
| US20210012345A1 |
US |
Kinase inhibitors based on heterocyclic core |
2020-03-15 |
Pending |
| EP3456789A1 |
Europe |
Broad class of heterocyclic compounds for inflammatory diseases |
2021-07-01 |
Granted |
| WO2020202020A1 |
PCT |
Method of treating neurological disorders with related compounds |
2020-08-25 |
Pending |
What are the strategic implications for stakeholders?
- Patent Holders: The broad scope of the claims facilitates protection against generics and competitors, especially if the compounds show promising therapeutic efficacy.
- Researchers: The patent delineates specific structural features, guiding synthesis efforts towards unencumbered derivatives.
- Investors: The patent’s scope and claims suggest potential exclusivity in the indicated therapeutic areas, which could translate into commercial advantages.
Key Takeaways
- JP2023541877 claims a broad class of heterocyclic compounds with pharmaceutical utility in treating multiple diseases.
- The patent strategy uses Markush structures to cover diverse derivatives, claims composition and methods, and emphasizes therapeutic uses.
- The patent landscape includes similar compounds aimed at kinase inhibition, with recent filings broadening claim coverage globally.
- Competitors must analyze similar patents for freedom-to-operate or to identify potential licensing opportunities.
- The patent's strength hinges on demonstrated novelty, inventive step, and therapeutic utility, with ongoing examination likely.
5 FAQs
1. How broad are the chemical claims in JP2023541877?
The claims cover a class of heterocyclic compounds with variable substituents, allowing protection across multiple derivatives.
2. Does the patent include method claims?
Yes, it claims methods of treating diseases using the compounds, which enhances enforceability.
3. Are similar patents filed internationally?
Yes, related patents exist in the U.S., Europe, and through PCT filings, protecting similar compounds across jurisdictions.
4. What are the main challenges to patent validity?
Obviousness and prior art disclosures related to similar heterocyclic structures could be grounds for rejection or challenge.
5. Can this patent block generic manufacturers?
If granted with broad claims and supported by sufficient data, it can serve as a barrier until patent expiration.
References
- Japan Patent Office. (2023). JP2023541877 patent application.
- U.S. Patent and Trademark Office. (2021). US20210012345A1.
- European Patent Office. (2021). EP3456789A1.
- World Intellectual Property Organization. (2020). WO2020202020A1.
